
company:hims
Hims will sell generic Semaglutide in 2026
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:hims
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
includes:study
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
category:news
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:risks
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.